Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07723976 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

StatusNot Yet Recruiting
PhasePhase 3
Started2026-10-30
View on ClinicalTrials.gov ↗

Amendment history

2026-07-22
Study Identification, Study Status v1
Study title-67 characters
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
2026-07-20
Original filing
Jazz Pharmaceuticals
34 trials monitored
See 1 trial at risk
Epilepsy
723 trials monitored
See 41 trials at risk
The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).
Trial Details
NCT Number NCT07723976
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Research UK Limited
Conditions Developmental and Epileptic Encephalopathy (DEE)
Enrollment 120 participants
Start Date 2026-10-30
Primary Completion 2029-09-04 (estimated)
Study Completion 2029-09-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-24